Chemicals
Showing 7651–7800 of 41137 results
-
9(Z),11(Z)-Conjugated linoleic acid is an isomer of linoleic acid (Item No. 90150) that has been found in milk from cows and other animals.{41611,41612} It is cytotoxic to Caco-2 human colon cancer cells (EC50 = 446.1 µM) and induces changes in the miRNA profile, including an upregulation hsa-miR-146a-5p and downregulation of hsa-miR-32-5p, which is involved in apoptosis.{41613} [Matreya, LLC. Catalog No. 1248]
Brand:CaymanSKU:24582 - 10 mgAvailable on backorder
9(Z),11(Z)-Conjugated linoleic acid is an isomer of linoleic acid (Item No. 90150) that has been found in milk from cows and other animals.{41611,41612} It is cytotoxic to Caco-2 human colon cancer cells (EC50 = 446.1 µM) and induces changes in the miRNA profile, including an upregulation hsa-miR-146a-5p and downregulation of hsa-miR-32-5p, which is involved in apoptosis.{41613} [Matreya, LLC. Catalog No. 1248]
Brand:CaymanSKU:24582 - 25 mgAvailable on backorder
9(Z),11(Z)-Conjugated linoleic acid is an isomer of linoleic acid (Item No. 90150) that has been found in milk from cows and other animals.{41611,41612} It is cytotoxic to Caco-2 human colon cancer cells (EC50 = 446.1 µM) and induces changes in the miRNA profile, including an upregulation hsa-miR-146a-5p and downregulation of hsa-miR-32-5p, which is involved in apoptosis.{41613} [Matreya, LLC. Catalog No. 1248]
Brand:CaymanSKU:24582 - 5 mgAvailable on backorder
9(Z),11(Z)-Conjugated linoleic acid methyl ester has been used as a standard for the quantification of conjugated linoleic acid methyl esters by GC-MS.{38903} [Matreya, LLC. Catalog No. 1256]
Brand:CaymanSKU:24583 - 25 mgAvailable on backorder
9(Z),12(Z),15(Z),18(Z),21(Z)-Tetracosapentaenoic acid is an ω-3 very long-chain polyunsaturated fatty acid. It has been used to study the desaturation and elongation of ω-3 polyunsaturated fatty acids.{47030} It is elongated to form C26:5 or acted on by Δ6 desaturase to form C24:6. 9(Z),12(Z),15(Z),18(Z),21(Z)-Tetracosapentaenoic acid is found at low levels in mouse brain and spleen and levels decrease in the brain and spleen of old and exceptionally old mice.{47031}
Brand:CaymanSKU:10005157 - 100 µgAvailable on backorder
9(Z),12(Z),15(Z),18(Z),21(Z)-Tetracosapentaenoic acid is an ω-3 very long-chain polyunsaturated fatty acid. It has been used to study the desaturation and elongation of ω-3 polyunsaturated fatty acids.{47030} It is elongated to form C26:5 or acted on by Δ6 desaturase to form C24:6. 9(Z),12(Z),15(Z),18(Z),21(Z)-Tetracosapentaenoic acid is found at low levels in mouse brain and spleen and levels decrease in the brain and spleen of old and exceptionally old mice.{47031}
Brand:CaymanSKU:10005157 - 25 µgAvailable on backorder
9(Z),12(Z),15(Z),18(Z),21(Z)-Tetracosapentaenoic acid is an ω-3 very long-chain polyunsaturated fatty acid. It has been used to study the desaturation and elongation of ω-3 polyunsaturated fatty acids.{47030} It is elongated to form C26:5 or acted on by Δ6 desaturase to form C24:6. 9(Z),12(Z),15(Z),18(Z),21(Z)-Tetracosapentaenoic acid is found at low levels in mouse brain and spleen and levels decrease in the brain and spleen of old and exceptionally old mice.{47031}
Brand:CaymanSKU:10005157 - 250 µgAvailable on backorder
9(Z),12(Z),15(Z),18(Z),21(Z)-Tetracosapentaenoic acid is an ω-3 very long-chain polyunsaturated fatty acid. It has been used to study the desaturation and elongation of ω-3 polyunsaturated fatty acids.{47030} It is elongated to form C26:5 or acted on by Δ6 desaturase to form C24:6. 9(Z),12(Z),15(Z),18(Z),21(Z)-Tetracosapentaenoic acid is found at low levels in mouse brain and spleen and levels decrease in the brain and spleen of old and exceptionally old mice.{47031}
Brand:CaymanSKU:10005157 - 50 µgAvailable on backorder
9c(i472) is an inhibitor of 15-lipoxygenase-1 (15-LO-1; IC50 = 0.19 µM).{35962} It decreases LPS- and IFN-γ-induced NF-ĸB activity in RAW-Blue™ cells when used at concentrations of 0.2, 1, and 5 µM. 9c(i472) reduces LPS- and IFN-γ-induced increases in Nos2 expression and lipid peroxidation in RAW 264.7 cells when used at a concentration of 5 µM.
Brand:CaymanSKU:28225 - 1 mgAvailable on backorder
9c(i472) is an inhibitor of 15-lipoxygenase-1 (15-LO-1; IC50 = 0.19 µM).{35962} It decreases LPS- and IFN-γ-induced NF-ĸB activity in RAW-Blue™ cells when used at concentrations of 0.2, 1, and 5 µM. 9c(i472) reduces LPS- and IFN-γ-induced increases in Nos2 expression and lipid peroxidation in RAW 264.7 cells when used at a concentration of 5 µM.
Brand:CaymanSKU:28225 - 500 µgAvailable on backorder
A 26771B is a macrolide antibiotic originally isolated from P. turbatum.{53119} It is active against S. aureus, S. faecalis, V. coli, M. gallisepticum, M. granularum, M. synoviae, M. hyosynoviae, M. hyopneumoniae, E. amylovora, P. multocida, and X. phaseoli bacteria (MICs = S. aureus (MRSA) strains (MICs = 6-16 μg/ml).{40114} A 26771B is also active against C. tropicalis, T. mentagrophytes, B. cinerea, C. ulmi, and V. albo-atrum fungi (MICs = 6.25-100 μg/ml).{53119}
Brand:CaymanSKU:29593 - 1 mgAvailable on backorder
A 83-01 is an inhibitor of TGF-β type I receptor kinase (ALK5), activin type IB receptor (ALK4), and nodal type I receptor (ALK7) (IC50s = 12, 45, and 7.5 nM, respectively).{31358} It blocks the phosphorylation of SMAD2/3 and inhibits TGF-β-induced epithelial-to-mesenchymal transition.{31358} It has little effect on bone morphogenic type I receptors, p38 mitogen-activated protein kinase, or ERK.{31358} A 83-01 has been used to reprogram fibroblasts into alternative lineages, including neural stem cells and cardiomyocytes.{31142,31158}
Brand:CaymanSKU:9001799 - 1 mgAvailable on backorder
A 83-01 is an inhibitor of TGF-β type I receptor kinase (ALK5), activin type IB receptor (ALK4), and nodal type I receptor (ALK7) (IC50s = 12, 45, and 7.5 nM, respectively).{31358} It blocks the phosphorylation of SMAD2/3 and inhibits TGF-β-induced epithelial-to-mesenchymal transition.{31358} It has little effect on bone morphogenic type I receptors, p38 mitogen-activated protein kinase, or ERK.{31358} A 83-01 has been used to reprogram fibroblasts into alternative lineages, including neural stem cells and cardiomyocytes.{31142,31158}
Brand:CaymanSKU:9001799 - 10 mgAvailable on backorder
A 83-01 is an inhibitor of TGF-β type I receptor kinase (ALK5), activin type IB receptor (ALK4), and nodal type I receptor (ALK7) (IC50s = 12, 45, and 7.5 nM, respectively).{31358} It blocks the phosphorylation of SMAD2/3 and inhibits TGF-β-induced epithelial-to-mesenchymal transition.{31358} It has little effect on bone morphogenic type I receptors, p38 mitogen-activated protein kinase, or ERK.{31358} A 83-01 has been used to reprogram fibroblasts into alternative lineages, including neural stem cells and cardiomyocytes.{31142,31158}
Brand:CaymanSKU:9001799 - 25 mgAvailable on backorder
A 83-01 is an inhibitor of TGF-β type I receptor kinase (ALK5), activin type IB receptor (ALK4), and nodal type I receptor (ALK7) (IC50s = 12, 45, and 7.5 nM, respectively).{31358} It blocks the phosphorylation of SMAD2/3 and inhibits TGF-β-induced epithelial-to-mesenchymal transition.{31358} It has little effect on bone morphogenic type I receptors, p38 mitogen-activated protein kinase, or ERK.{31358} A 83-01 has been used to reprogram fibroblasts into alternative lineages, including neural stem cells and cardiomyocytes.{31142,31158}
Brand:CaymanSKU:9001799 - 5 mgAvailable on backorder
Brand:CaymanSKU:29783 - 1 mgAvailable on backorder
Brand:CaymanSKU:29783 - 10 mgAvailable on backorder
Brand:CaymanSKU:29783 - 25 mgAvailable on backorder
Brand:CaymanSKU:29783 - 5 mgAvailable on backorder
A-1120 is a non-retinoid retinol binding protein 4 (RBP4) antagonist (Ki = 8.3 nM for disruption of RBP4 binding to transthyretin).{58011} It is selective for RBP4 over cellular retinol binding protein 1 (CRBP1; IC50s = 0.09 and >30 µM, respectively, in radioligand binding assays), as well as a panel of G protein-coupled receptors, kinases, and enzymes. A-1120 (30 mg/kg) reduces serum levels of RBP4 and retinol in mice. It also inhibits retinal bisretinoid accumulation in the Abca4-/- mouse model of enhanced retinal lipofuscinogenesis-induced macular degeneration.{58012}
Brand:CaymanSKU:30921 - 10 mgAvailable on backorder
A-1120 is a non-retinoid retinol binding protein 4 (RBP4) antagonist (Ki = 8.3 nM for disruption of RBP4 binding to transthyretin).{58011} It is selective for RBP4 over cellular retinol binding protein 1 (CRBP1; IC50s = 0.09 and >30 µM, respectively, in radioligand binding assays), as well as a panel of G protein-coupled receptors, kinases, and enzymes. A-1120 (30 mg/kg) reduces serum levels of RBP4 and retinol in mice. It also inhibits retinal bisretinoid accumulation in the Abca4-/- mouse model of enhanced retinal lipofuscinogenesis-induced macular degeneration.{58012}
Brand:CaymanSKU:30921 - 5 mgAvailable on backorder
A-1155463 is an inhibitor of Bcl-xL (Ki = is = 80 and 16 nM, respectively). A-1155463 inhibits the growth of H146 small cell lung cancer cells (EC50 = 65 nM). In vivo, A-1155463 (5 mg/kg, i.p.) reduces tumor volume in an H146 mouse xenograft model. A-1155463 also induces premature apoptosis in influenza A-infected cells (EC50 = <10 nM).{46183}
Brand:CaymanSKU:27369 - 1 mgAvailable on backorder
A-1155463 is an inhibitor of Bcl-xL (Ki = is = 80 and 16 nM, respectively). A-1155463 inhibits the growth of H146 small cell lung cancer cells (EC50 = 65 nM). In vivo, A-1155463 (5 mg/kg, i.p.) reduces tumor volume in an H146 mouse xenograft model. A-1155463 also induces premature apoptosis in influenza A-infected cells (EC50 = <10 nM).{46183}
Brand:CaymanSKU:27369 - 10 mgAvailable on backorder
A-1155463 is an inhibitor of Bcl-xL (Ki = is = 80 and 16 nM, respectively). A-1155463 inhibits the growth of H146 small cell lung cancer cells (EC50 = 65 nM). In vivo, A-1155463 (5 mg/kg, i.p.) reduces tumor volume in an H146 mouse xenograft model. A-1155463 also induces premature apoptosis in influenza A-infected cells (EC50 = <10 nM).{46183}
Brand:CaymanSKU:27369 - 25 mgAvailable on backorder
A-1155463 is an inhibitor of Bcl-xL (Ki = is = 80 and 16 nM, respectively). A-1155463 inhibits the growth of H146 small cell lung cancer cells (EC50 = 65 nM). In vivo, A-1155463 (5 mg/kg, i.p.) reduces tumor volume in an H146 mouse xenograft model. A-1155463 also induces premature apoptosis in influenza A-infected cells (EC50 = <10 nM).{46183}
Brand:CaymanSKU:27369 - 5 mgAvailable on backorder
A-1210477 is an inhibitor of the antiapoptotic Bcl-2 family protein myeloid cell leukemia-1 (Mcl-1; Ki = 0.43 nM and IC50 = 26.2 nM) that demonstrates >100-fold selectivity over other Bcl-2 family members (Kis > 0.66 µM for Bcl-2, Bcl-XL, Bcl-W, and Bfl-1).{32901,32902,32900} It has been shown to disrupt the interaction between Mcl-1 and pro-apoptotic BIM, inducing the hallmarks of apoptosis in Mcl-1-dependent multiple myeloma and non-small cell lung cancer cell lines.{32901,32900}
Brand:CaymanSKU:21113 -Out of stock
A-1210477 is an inhibitor of the antiapoptotic Bcl-2 family protein myeloid cell leukemia-1 (Mcl-1; Ki = 0.43 nM and IC50 = 26.2 nM) that demonstrates >100-fold selectivity over other Bcl-2 family members (Kis > 0.66 µM for Bcl-2, Bcl-XL, Bcl-W, and Bfl-1).{32901,32902,32900} It has been shown to disrupt the interaction between Mcl-1 and pro-apoptotic BIM, inducing the hallmarks of apoptosis in Mcl-1-dependent multiple myeloma and non-small cell lung cancer cell lines.{32901,32900}
Brand:CaymanSKU:21113 -Out of stock
A-1210477 is an inhibitor of the antiapoptotic Bcl-2 family protein myeloid cell leukemia-1 (Mcl-1; Ki = 0.43 nM and IC50 = 26.2 nM) that demonstrates >100-fold selectivity over other Bcl-2 family members (Kis > 0.66 µM for Bcl-2, Bcl-XL, Bcl-W, and Bfl-1).{32901,32902,32900} It has been shown to disrupt the interaction between Mcl-1 and pro-apoptotic BIM, inducing the hallmarks of apoptosis in Mcl-1-dependent multiple myeloma and non-small cell lung cancer cell lines.{32901,32900}
Brand:CaymanSKU:21113 -Out of stock
A-1210477 is an inhibitor of the antiapoptotic Bcl-2 family protein myeloid cell leukemia-1 (Mcl-1; Ki = 0.43 nM and IC50 = 26.2 nM) that demonstrates >100-fold selectivity over other Bcl-2 family members (Kis > 0.66 µM for Bcl-2, Bcl-XL, Bcl-W, and Bfl-1).{32901,32902,32900} It has been shown to disrupt the interaction between Mcl-1 and pro-apoptotic BIM, inducing the hallmarks of apoptosis in Mcl-1-dependent multiple myeloma and non-small cell lung cancer cell lines.{32901,32900}
Brand:CaymanSKU:21113 -Out of stock
A-1331852 is an orally bioavailable Bcl-xL inhibitor that selectively binds Bcl-xL over Bcl-2, Mcl-1, and Bcl-W (Kis = in vitro (EC50s = 6 and >5,000 nM, respectively). A-1331852 (25 mg/kg twice per day) inhibits tumor growth in a MOLT-4 mouse xenograft model. It also inhibits tumor growth and increases the antitumor activity of docetaxel (Item No. 11637) in MDA-MB-231 LC3 metastatic breast cancer and NCI-H1650 non-small cell lung cancer mouse xenograft models when administered at a dose of 25 mg/kg. A-1331852 also increases venetoclax inhibition of tumor growth in an NCI-H1963.FP5 small cell lung cancer mouse xenograft model.
Brand:CaymanSKU:22963 - 1 mgAvailable on backorder
A-1331852 is an orally bioavailable Bcl-xL inhibitor that selectively binds Bcl-xL over Bcl-2, Mcl-1, and Bcl-W (Kis = in vitro (EC50s = 6 and >5,000 nM, respectively). A-1331852 (25 mg/kg twice per day) inhibits tumor growth in a MOLT-4 mouse xenograft model. It also inhibits tumor growth and increases the antitumor activity of docetaxel (Item No. 11637) in MDA-MB-231 LC3 metastatic breast cancer and NCI-H1650 non-small cell lung cancer mouse xenograft models when administered at a dose of 25 mg/kg. A-1331852 also increases venetoclax inhibition of tumor growth in an NCI-H1963.FP5 small cell lung cancer mouse xenograft model.
Brand:CaymanSKU:22963 - 10 mgAvailable on backorder
A-1331852 is an orally bioavailable Bcl-xL inhibitor that selectively binds Bcl-xL over Bcl-2, Mcl-1, and Bcl-W (Kis = in vitro (EC50s = 6 and >5,000 nM, respectively). A-1331852 (25 mg/kg twice per day) inhibits tumor growth in a MOLT-4 mouse xenograft model. It also inhibits tumor growth and increases the antitumor activity of docetaxel (Item No. 11637) in MDA-MB-231 LC3 metastatic breast cancer and NCI-H1650 non-small cell lung cancer mouse xenograft models when administered at a dose of 25 mg/kg. A-1331852 also increases venetoclax inhibition of tumor growth in an NCI-H1963.FP5 small cell lung cancer mouse xenograft model.
Brand:CaymanSKU:22963 - 5 mgAvailable on backorder
A-196 is a selective inhibitor of SUV420H1 and SUV420H2 (IC50s = 25 and 144 nM, respectively) that is more than 100-fold selective over other histone methyltransferases and non-epigenetic targets. A-196 has been shown to inhibit the di- and tri-methylation of lysine 20 of histone H4 (H4K20me) in multiple cell lines with IC50 values less than 1 μM. For more information on A-196 please visit the Structural Genomics Consortium (SGC). The negative control, SGC2043 (A-197), for A-196 is also available exclusively through the SGC. You can submit a request to receive the negative control here.
Brand:CaymanSKU:-Available on backorder
A-196 is a selective inhibitor of SUV420H1 and SUV420H2 (IC50s = 25 and 144 nM, respectively) that is more than 100-fold selective over other histone methyltransferases and non-epigenetic targets. A-196 has been shown to inhibit the di- and tri-methylation of lysine 20 of histone H4 (H4K20me) in multiple cell lines with IC50 values less than 1 μM. For more information on A-196 please visit the Structural Genomics Consortium (SGC). The negative control, SGC2043 (A-197), for A-196 is also available exclusively through the SGC. You can submit a request to receive the negative control here.
Brand:CaymanSKU:-Available on backorder
A-196 is a selective inhibitor of SUV420H1 and SUV420H2 (IC50s = 25 and 144 nM, respectively) that is more than 100-fold selective over other histone methyltransferases and non-epigenetic targets. A-196 has been shown to inhibit the di- and tri-methylation of lysine 20 of histone H4 (H4K20me) in multiple cell lines with IC50 values less than 1 μM. For more information on A-196 please visit the Structural Genomics Consortium (SGC). The negative control, SGC2043 (A-197), for A-196 is also available exclusively through the SGC. You can submit a request to receive the negative control here.
Brand:CaymanSKU:-Available on backorder
A-205804 is a potent inhibitor of E-selectin and ICAM-1 expression in human vascular endothelial cells stimulated with TNF-α (IC50s = 20 and 25 nM, respectively).{33381} It does not block expression of VCAM-1 (IC50 > 1,000 nM).
Brand:CaymanSKU:21252 -Out of stock
A-205804 is a potent inhibitor of E-selectin and ICAM-1 expression in human vascular endothelial cells stimulated with TNF-α (IC50s = 20 and 25 nM, respectively).{33381} It does not block expression of VCAM-1 (IC50 > 1,000 nM).
Brand:CaymanSKU:21252 -Out of stock
A-205804 is a potent inhibitor of E-selectin and ICAM-1 expression in human vascular endothelial cells stimulated with TNF-α (IC50s = 20 and 25 nM, respectively).{33381} It does not block expression of VCAM-1 (IC50 > 1,000 nM).
Brand:CaymanSKU:21252 -Out of stock
A-205804 is a potent inhibitor of E-selectin and ICAM-1 expression in human vascular endothelial cells stimulated with TNF-α (IC50s = 20 and 25 nM, respectively).{33381} It does not block expression of VCAM-1 (IC50 > 1,000 nM).
Brand:CaymanSKU:21252 -Out of stock
A-317491 is a non-nucleotide antagonist of the purinergic receptors P2X3 and P2X2/3 (Kis = 22-92 nM in a calcium influx assay) that is selective over other purinergic and neurotransmitter receptors, ion channels, and enzymes (IC50s = >10 µM).{39363} It reduces thermal hyperalgesia induced by complete Freund’s adjuvant in rats (ED50 = 30 µmol/kg, s.c.) and nociceptive responses to chemically-induced pain. Chronic administration of A-317491 (30 µmol/kg, twice daily) reduces early, but not late, phase pain in a mouse model of bone cancer.{39362} A-317491 does not readily cross the blood-brain barrier and reduces pain responses when applied topically in a rat model of inflammatory pain, indicating that it acts primarily at peripheral purinergic receptors.{39364}
Brand:CaymanSKU:-Available on backorder
A-317491 is a non-nucleotide antagonist of the purinergic receptors P2X3 and P2X2/3 (Kis = 22-92 nM in a calcium influx assay) that is selective over other purinergic and neurotransmitter receptors, ion channels, and enzymes (IC50s = >10 µM).{39363} It reduces thermal hyperalgesia induced by complete Freund’s adjuvant in rats (ED50 = 30 µmol/kg, s.c.) and nociceptive responses to chemically-induced pain. Chronic administration of A-317491 (30 µmol/kg, twice daily) reduces early, but not late, phase pain in a mouse model of bone cancer.{39362} A-317491 does not readily cross the blood-brain barrier and reduces pain responses when applied topically in a rat model of inflammatory pain, indicating that it acts primarily at peripheral purinergic receptors.{39364}
Brand:CaymanSKU:-Available on backorder
A-317491 is a non-nucleotide antagonist of the purinergic receptors P2X3 and P2X2/3 (Kis = 22-92 nM in a calcium influx assay) that is selective over other purinergic and neurotransmitter receptors, ion channels, and enzymes (IC50s = >10 µM).{39363} It reduces thermal hyperalgesia induced by complete Freund’s adjuvant in rats (ED50 = 30 µmol/kg, s.c.) and nociceptive responses to chemically-induced pain. Chronic administration of A-317491 (30 µmol/kg, twice daily) reduces early, but not late, phase pain in a mouse model of bone cancer.{39362} A-317491 does not readily cross the blood-brain barrier and reduces pain responses when applied topically in a rat model of inflammatory pain, indicating that it acts primarily at peripheral purinergic receptors.{39364}
Brand:CaymanSKU:-Available on backorder
A-317491 is a non-nucleotide antagonist of the purinergic receptors P2X3 and P2X2/3 (Kis = 22-92 nM in a calcium influx assay) that is selective over other purinergic and neurotransmitter receptors, ion channels, and enzymes (IC50s = >10 µM).{39363} It reduces thermal hyperalgesia induced by complete Freund’s adjuvant in rats (ED50 = 30 µmol/kg, s.c.) and nociceptive responses to chemically-induced pain. Chronic administration of A-317491 (30 µmol/kg, twice daily) reduces early, but not late, phase pain in a mouse model of bone cancer.{39362} A-317491 does not readily cross the blood-brain barrier and reduces pain responses when applied topically in a rat model of inflammatory pain, indicating that it acts primarily at peripheral purinergic receptors.{39364}
Brand:CaymanSKU:-Available on backorder
A-366 is a potent, peptide-competitive inhibitor of the lysine methyltransferase G9a (IC50 = 3.3 nM).{26028} It displays greater than 1,000-fold selectivity over 21 other methyltransferases.{26028} A-366 significantly reduces the cellular levels of dimethylation on histone 3 at lysine 9 (H3K9Me2) in PC3 cells without reducing total histone 3, H3K27Me3, or H3K36Me2.{26028} It also blocks the interaction of the methyl lysine reader protein Spindlin1 with H3K4me3 by binding with a Spindlin1 Tudor domain (Kd = 111 nM).{30715} See the Structural Genomics Consortium (SGC) website for more information.
Brand:CaymanSKU:- A-366 is a potent, peptide-competitive inhibitor of the lysine methyltransferase G9a (IC50 = 3.3 nM).{26028} It displays greater than 1,000-fold selectivity over 21 other methyltransferases.{26028} A-366 significantly reduces the cellular levels of dimethylation on histone 3 at lysine 9 (H3K9Me2) in PC3 cells without reducing total histone 3, H3K27Me3, or H3K36Me2.{26028} It also blocks the interaction of the methyl lysine reader protein Spindlin1 with H3K4me3 by binding with a Spindlin1 Tudor domain (Kd = 111 nM).{30715} See the Structural Genomics Consortium (SGC) website for more information.
Brand:CaymanSKU:- A-366 is a potent, peptide-competitive inhibitor of the lysine methyltransferase G9a (IC50 = 3.3 nM).{26028} It displays greater than 1,000-fold selectivity over 21 other methyltransferases.{26028} A-366 significantly reduces the cellular levels of dimethylation on histone 3 at lysine 9 (H3K9Me2) in PC3 cells without reducing total histone 3, H3K27Me3, or H3K36Me2.{26028} It also blocks the interaction of the methyl lysine reader protein Spindlin1 with H3K4me3 by binding with a Spindlin1 Tudor domain (Kd = 111 nM).{30715} See the Structural Genomics Consortium (SGC) website for more information.
Brand:CaymanSKU:-
A-39183A is an active component of the A-39183 antibiotic complex produced by aerobic fermentation of Streptomyces NRRL 12049.{38264} It has activity against penicillin-resistant S. aureus 3055 and S. faecalis X66 (MICs = 32 and 32 μg/ml, respectively) and a variety of Gram-positive and Gram-negative anaerobic bacteria (MICs = 16-128 μg/ml) in an agar dilution assay.
Brand:CaymanSKU:23239 - 1 mgAvailable on backorder
A-39183A is an active component of the A-39183 antibiotic complex produced by aerobic fermentation of Streptomyces NRRL 12049.{38264} It has activity against penicillin-resistant S. aureus 3055 and S. faecalis X66 (MICs = 32 and 32 μg/ml, respectively) and a variety of Gram-positive and Gram-negative anaerobic bacteria (MICs = 16-128 μg/ml) in an agar dilution assay.
Brand:CaymanSKU:23239 - 5 mgAvailable on backorder
A-419259 is an inhibitor of Src family kinases, including Src, LCK, Lyn, and Hck (IC50s = 9, 50 = 3,000 nM) and PKC (IC50 = >33 μM).{29932} A-419259 inhibits growth of Philadelphia chromosome-positive (Ph+) K-562 and Meg-01 myeloid leukemia cells (IC50s = 0.1-0.3 and 0.1 μM, respectively), but not Ph- TF-1 and HEL cells. It induces apoptosis in K-562 cells in a concentration-dependent manner. A-419259 (300 nM) inhibits differentiation of murine embryonic stem cells while maintaining pluripotency.{29929} It reduces the total number of acute myeloid leukemia (AML) cells, as well as AML stem cells, in the bone marrow and spleen in mouse patient-derived xenograft (PDX) models of AML when administered at a dose of 30 mg/kg twice daily.{41984}
Brand:CaymanSKU:25605 - 1 mgAvailable on backorder
A-419259 is an inhibitor of Src family kinases, including Src, LCK, Lyn, and Hck (IC50s = 9, 50 = 3,000 nM) and PKC (IC50 = >33 μM).{29932} A-419259 inhibits growth of Philadelphia chromosome-positive (Ph+) K-562 and Meg-01 myeloid leukemia cells (IC50s = 0.1-0.3 and 0.1 μM, respectively), but not Ph- TF-1 and HEL cells. It induces apoptosis in K-562 cells in a concentration-dependent manner. A-419259 (300 nM) inhibits differentiation of murine embryonic stem cells while maintaining pluripotency.{29929} It reduces the total number of acute myeloid leukemia (AML) cells, as well as AML stem cells, in the bone marrow and spleen in mouse patient-derived xenograft (PDX) models of AML when administered at a dose of 30 mg/kg twice daily.{41984}
Brand:CaymanSKU:25605 - 10 mgAvailable on backorder
A-419259 is an inhibitor of Src family kinases, including Src, LCK, Lyn, and Hck (IC50s = 9, 50 = 3,000 nM) and PKC (IC50 = >33 μM).{29932} A-419259 inhibits growth of Philadelphia chromosome-positive (Ph+) K-562 and Meg-01 myeloid leukemia cells (IC50s = 0.1-0.3 and 0.1 μM, respectively), but not Ph- TF-1 and HEL cells. It induces apoptosis in K-562 cells in a concentration-dependent manner. A-419259 (300 nM) inhibits differentiation of murine embryonic stem cells while maintaining pluripotency.{29929} It reduces the total number of acute myeloid leukemia (AML) cells, as well as AML stem cells, in the bone marrow and spleen in mouse patient-derived xenograft (PDX) models of AML when administered at a dose of 30 mg/kg twice daily.{41984}
Brand:CaymanSKU:25605 - 5 mgAvailable on backorder
A-419259 is an inhibitor of Src family kinases, including Src, LCK, Lyn, and Hck (IC50s = 9, 50 = 3,000 nM) and PKC (IC50 = >33 μM).{29932} A-419259 inhibits growth of Philadelphia chromosome-positive (Ph+) K-562 and Meg-01 myeloid leukemia cells (IC50s = 0.1-0.3 and 0.1 μM, respectively), but not Ph- TF-1 and HEL cells. It induces apoptosis in K-562 cells in a concentration-dependent manner. A-419259 (300 nM) inhibits differentiation of murine embryonic stem cells while maintaining pluripotency.{29929} It reduces the total number of acute myeloid leukemia (AML) cells, as well as AML stem cells, in the bone marrow and spleen in mouse patient-derived xenograft (PDX) models of AML when administered at a dose of 30 mg/kg twice daily.{41984}
Brand:CaymanSKU:25605 - 500 µgAvailable on backorder
A-419259 is an inhibitor of Src family kinases, including Src, LCK, Lyn, and Hck (IC50s = 9, 50 = 3,000 nM) and PKC (IC50 = >33 μM).{29932} A-419259 inhibits growth of Philadelphia chromosome-positive (Ph+) K-562 and Meg-01 myeloid leukemia cells (IC50s = 0.1-0.3 and 0.1 μM, respectively), but not Ph- TF-1 and HEL cells. It induces apoptosis in K-562 cells in a concentration-dependent manner. A-419259 (300 nM) inhibits differentiation of murine embryonic stem cells while maintaining pluripotency.{29929} It reduces the total number of acute myeloid leukemia (AML) cells, as well as AML stem cells, in the bone marrow and spleen in mouse patient-derived xenograft (PDX) models of AML when administered at a dose of 30 mg/kg twice daily.{41984}
Brand:CaymanSKU:-Available on backorder
A-419259 is an inhibitor of Src family kinases, including Src, LCK, Lyn, and Hck (IC50s = 9, 50 = 3,000 nM) and PKC (IC50 = >33 μM).{29932} A-419259 inhibits growth of Philadelphia chromosome-positive (Ph+) K-562 and Meg-01 myeloid leukemia cells (IC50s = 0.1-0.3 and 0.1 μM, respectively), but not Ph- TF-1 and HEL cells. It induces apoptosis in K-562 cells in a concentration-dependent manner. A-419259 (300 nM) inhibits differentiation of murine embryonic stem cells while maintaining pluripotency.{29929} It reduces the total number of acute myeloid leukemia (AML) cells, as well as AML stem cells, in the bone marrow and spleen in mouse patient-derived xenograft (PDX) models of AML when administered at a dose of 30 mg/kg twice daily.{41984}
Brand:CaymanSKU:-Available on backorder
A-419259 is an inhibitor of Src family kinases, including Src, LCK, Lyn, and Hck (IC50s = 9, 50 = 3,000 nM) and PKC (IC50 = >33 μM).{29932} A-419259 inhibits growth of Philadelphia chromosome-positive (Ph+) K-562 and Meg-01 myeloid leukemia cells (IC50s = 0.1-0.3 and 0.1 μM, respectively), but not Ph- TF-1 and HEL cells. It induces apoptosis in K-562 cells in a concentration-dependent manner. A-419259 (300 nM) inhibits differentiation of murine embryonic stem cells while maintaining pluripotency.{29929} It reduces the total number of acute myeloid leukemia (AML) cells, as well as AML stem cells, in the bone marrow and spleen in mouse patient-derived xenograft (PDX) models of AML when administered at a dose of 30 mg/kg twice daily.{41984}
Brand:CaymanSKU:-Available on backorder
A-419259 is an inhibitor of Src family kinases, including Src, LCK, Lyn, and Hck (IC50s = 9, 50 = 3,000 nM) and PKC (IC50 = >33 μM).{29932} A-419259 inhibits growth of Philadelphia chromosome-positive (Ph+) K-562 and Meg-01 myeloid leukemia cells (IC50s = 0.1-0.3 and 0.1 μM, respectively), but not Ph- TF-1 and HEL cells. It induces apoptosis in K-562 cells in a concentration-dependent manner. A-419259 (300 nM) inhibits differentiation of murine embryonic stem cells while maintaining pluripotency.{29929} It reduces the total number of acute myeloid leukemia (AML) cells, as well as AML stem cells, in the bone marrow and spleen in mouse patient-derived xenograft (PDX) models of AML when administered at a dose of 30 mg/kg twice daily.{41984}
Brand:CaymanSKU:-Available on backorder
A-438079 is a competitive antagonist of the nucleotide receptor P2X7 (pIC50 = 6.9).{22914} It inhibits both calcium flux and IL-1β release mediated by P2X7 while not affecting the activity of other P2X receptors.{22914,22913} A-438079 is effective in evaluating the role of P2X7 in nociception, oxidative stress, and apoptosis in cells and animals.{22915,22916,22917}
Brand:CaymanSKU:- A-438079 is a competitive antagonist of the nucleotide receptor P2X7 (pIC50 = 6.9).{22914} It inhibits both calcium flux and IL-1β release mediated by P2X7 while not affecting the activity of other P2X receptors.{22914,22913} A-438079 is effective in evaluating the role of P2X7 in nociception, oxidative stress, and apoptosis in cells and animals.{22915,22916,22917}
Brand:CaymanSKU:- A-438079 is a competitive antagonist of the nucleotide receptor P2X7 (pIC50 = 6.9).{22914} It inhibits both calcium flux and IL-1β release mediated by P2X7 while not affecting the activity of other P2X receptors.{22914,22913} A-438079 is effective in evaluating the role of P2X7 in nociception, oxidative stress, and apoptosis in cells and animals.{22915,22916,22917}
Brand:CaymanSKU:- A-438079 is a competitive antagonist of the nucleotide receptor P2X7 (pIC50 = 6.9).{22914} It inhibits both calcium flux and IL-1β release mediated by P2X7 while not affecting the activity of other P2X receptors.{22914,22913} A-438079 is effective in evaluating the role of P2X7 in nociception, oxidative stress, and apoptosis in cells and animals.{22915,22916,22917}
Brand:CaymanSKU:-
Three related forms of the kinase Akt (1, 2, 3, also known as protein kinase B isoforms PKBα, β, γ) modulate cell proliferation, metabolism, and survival as well as angiogenesis. A-443654 is an inhibitor of Akt (Ki = 160 pmol/L for all three isoforms) that interferes with mitotic progression and bipolar spindle formation.{26942,26944} It induces G2/M accumulation, defects in centrosome separation, and formation of either monopolar arrays or disorganized spindles.{26944} A-443654 has been reported to slow the progression of Akt-dependent tumors in in vivo mouse models.{26942} In response to an A-443654-induced decrease in phosphorylation of Akt targets, a concomitant increase in Thr308 and Ser473 phosphorylation of Akt has been observed in human cancer cell lines.{26943} A-443654 has been used to examine the mechanism of this rapid feedback reaction.
Brand:CaymanSKU:-Out of stock
Three related forms of the kinase Akt (1, 2, 3, also known as protein kinase B isoforms PKBα, β, γ) modulate cell proliferation, metabolism, and survival as well as angiogenesis. A-443654 is an inhibitor of Akt (Ki = 160 pmol/L for all three isoforms) that interferes with mitotic progression and bipolar spindle formation.{26942,26944} It induces G2/M accumulation, defects in centrosome separation, and formation of either monopolar arrays or disorganized spindles.{26944} A-443654 has been reported to slow the progression of Akt-dependent tumors in in vivo mouse models.{26942} In response to an A-443654-induced decrease in phosphorylation of Akt targets, a concomitant increase in Thr308 and Ser473 phosphorylation of Akt has been observed in human cancer cell lines.{26943} A-443654 has been used to examine the mechanism of this rapid feedback reaction.
Brand:CaymanSKU:-Out of stock
Three related forms of the kinase Akt (1, 2, 3, also known as protein kinase B isoforms PKBα, β, γ) modulate cell proliferation, metabolism, and survival as well as angiogenesis. A-443654 is an inhibitor of Akt (Ki = 160 pmol/L for all three isoforms) that interferes with mitotic progression and bipolar spindle formation.{26942,26944} It induces G2/M accumulation, defects in centrosome separation, and formation of either monopolar arrays or disorganized spindles.{26944} A-443654 has been reported to slow the progression of Akt-dependent tumors in in vivo mouse models.{26942} In response to an A-443654-induced decrease in phosphorylation of Akt targets, a concomitant increase in Thr308 and Ser473 phosphorylation of Akt has been observed in human cancer cell lines.{26943} A-443654 has been used to examine the mechanism of this rapid feedback reaction.
Brand:CaymanSKU:-Out of stock
A-484954 is an ATP-competitive inhibitor of eukaryotic elongation factor-2 kinase (eEF-2K; IC50 = 420 nM).{51146} It reduces eEF-2K autophosphorylation in PC3, HeLa, H460, H1299, and MDA-MB-231 cancer cells when used at a concentration of 75 μM.
Brand:CaymanSKU:28279 - 1 mgAvailable on backorder
A-484954 is an ATP-competitive inhibitor of eukaryotic elongation factor-2 kinase (eEF-2K; IC50 = 420 nM).{51146} It reduces eEF-2K autophosphorylation in PC3, HeLa, H460, H1299, and MDA-MB-231 cancer cells when used at a concentration of 75 μM.
Brand:CaymanSKU:28279 - 10 mgAvailable on backorder
A-484954 is an ATP-competitive inhibitor of eukaryotic elongation factor-2 kinase (eEF-2K; IC50 = 420 nM).{51146} It reduces eEF-2K autophosphorylation in PC3, HeLa, H460, H1299, and MDA-MB-231 cancer cells when used at a concentration of 75 μM.
Brand:CaymanSKU:28279 - 25 mgAvailable on backorder
A-484954 is an ATP-competitive inhibitor of eukaryotic elongation factor-2 kinase (eEF-2K; IC50 = 420 nM).{51146} It reduces eEF-2K autophosphorylation in PC3, HeLa, H460, H1299, and MDA-MB-231 cancer cells when used at a concentration of 75 μM.
Brand:CaymanSKU:28279 - 5 mgAvailable on backorder
A-485 is an inhibitor of the histone acetyltransferase p300/CBP (IC50 = 60 nM).{40422} It decreases acetylated histone H3 lysine 27 (H3K27Ac), but not H3K9Ac, levels in PC3 cells in a concentration-dependent manner. A-485 reduces proliferation of non-small cell lung cancer (NSCLC), small cell lung cancer, triple-negative breast cancer, mantel cell lymphoma, multiple myeloma, non-Hodgkin’s, and acute myeloid leukemia cell lines. It inhibits expression of prostate specific antigen (PSA) and H3K27Ac occupancy at the PSA enhancer without inhibiting androgen receptor occupancy in LNCaP-FGC cells. A-485 reduces tumor volume in a LuCaP-77 mouse xenograft model of castration-resistant prostate cancer when administered at a dose of 100 mg twice per day for 21 days.
Brand:CaymanSKU:24119 - 1 mgAvailable on backorder
A-485 is an inhibitor of the histone acetyltransferase p300/CBP (IC50 = 60 nM).{40422} It decreases acetylated histone H3 lysine 27 (H3K27Ac), but not H3K9Ac, levels in PC3 cells in a concentration-dependent manner. A-485 reduces proliferation of non-small cell lung cancer (NSCLC), small cell lung cancer, triple-negative breast cancer, mantel cell lymphoma, multiple myeloma, non-Hodgkin’s, and acute myeloid leukemia cell lines. It inhibits expression of prostate specific antigen (PSA) and H3K27Ac occupancy at the PSA enhancer without inhibiting androgen receptor occupancy in LNCaP-FGC cells. A-485 reduces tumor volume in a LuCaP-77 mouse xenograft model of castration-resistant prostate cancer when administered at a dose of 100 mg twice per day for 21 days.
Brand:CaymanSKU:24119 - 10 mgAvailable on backorder
A-485 is an inhibitor of the histone acetyltransferase p300/CBP (IC50 = 60 nM).{40422} It decreases acetylated histone H3 lysine 27 (H3K27Ac), but not H3K9Ac, levels in PC3 cells in a concentration-dependent manner. A-485 reduces proliferation of non-small cell lung cancer (NSCLC), small cell lung cancer, triple-negative breast cancer, mantel cell lymphoma, multiple myeloma, non-Hodgkin’s, and acute myeloid leukemia cell lines. It inhibits expression of prostate specific antigen (PSA) and H3K27Ac occupancy at the PSA enhancer without inhibiting androgen receptor occupancy in LNCaP-FGC cells. A-485 reduces tumor volume in a LuCaP-77 mouse xenograft model of castration-resistant prostate cancer when administered at a dose of 100 mg twice per day for 21 days.
Brand:CaymanSKU:24119 - 25 mgAvailable on backorder
A-485 is an inhibitor of the histone acetyltransferase p300/CBP (IC50 = 60 nM).{40422} It decreases acetylated histone H3 lysine 27 (H3K27Ac), but not H3K9Ac, levels in PC3 cells in a concentration-dependent manner. A-485 reduces proliferation of non-small cell lung cancer (NSCLC), small cell lung cancer, triple-negative breast cancer, mantel cell lymphoma, multiple myeloma, non-Hodgkin’s, and acute myeloid leukemia cell lines. It inhibits expression of prostate specific antigen (PSA) and H3K27Ac occupancy at the PSA enhancer without inhibiting androgen receptor occupancy in LNCaP-FGC cells. A-485 reduces tumor volume in a LuCaP-77 mouse xenograft model of castration-resistant prostate cancer when administered at a dose of 100 mg twice per day for 21 days.
Brand:CaymanSKU:24119 - 5 mgAvailable on backorder
A-54556A is a natural acyldepsipeptide (ADEP) antibiotic isolated from the fermentation broth of S. hawaiiensis.{24688} Like other ADEP antibiotics, A-54556A binds to the ATP-dependent Clp protease proteolytic subunit ClpP, resulting in constitutive activation of this bacterial protease.{27768,27766,27765} This leads to uncontrolled proteolysis, inhibition of bacterial cell division, and, ultimately, cell death.{24688,27767} A-54556A preferentially targets Gram-positive bacteria, including staphylococci, streptococci, and enterococci, with minimum inhibitory concentration values in the submicrogram/milliliter range.{27767} ADEP antibiotics are effective against chronic infections as they are able to eradicate chronic biofilm infections, particularly when combined with rifampicin.{24689}
Brand:CaymanSKU:- A-54556A is a natural acyldepsipeptide (ADEP) antibiotic isolated from the fermentation broth of S. hawaiiensis.{24688} Like other ADEP antibiotics, A-54556A binds to the ATP-dependent Clp protease proteolytic subunit ClpP, resulting in constitutive activation of this bacterial protease.{27768,27766,27765} This leads to uncontrolled proteolysis, inhibition of bacterial cell division, and, ultimately, cell death.{24688,27767} A-54556A preferentially targets Gram-positive bacteria, including staphylococci, streptococci, and enterococci, with minimum inhibitory concentration values in the submicrogram/milliliter range.{27767} ADEP antibiotics are effective against chronic infections as they are able to eradicate chronic biofilm infections, particularly when combined with rifampicin.{24689}
Brand:CaymanSKU:-
A-54556B is a natural acyldepsipeptide (ADEP) antibiotic isolated from the fermentation broth of S. hawaiiensis.{27771} Like the closely related ADEP, A-54556A (Item No. 15305), A-54556B is effective against Gram-positive bacteria, including penicillin-resistant S. aureus.{27771} A-54556B is also effective against many strains of anaerobic bacteria.{27771}
Brand:CaymanSKU:-Out of stock
A-54556B is a natural acyldepsipeptide (ADEP) antibiotic isolated from the fermentation broth of S. hawaiiensis.{27771} Like the closely related ADEP, A-54556A (Item No. 15305), A-54556B is effective against Gram-positive bacteria, including penicillin-resistant S. aureus.{27771} A-54556B is also effective against many strains of anaerobic bacteria.{27771}
Brand:CaymanSKU:-Out of stock
The α1-adrenergic receptors are Gq protein-coupled receptors that play a key role in the modulation of sympathetic nervous system activity and are the site of action for therapeutic agents, such as antihypertensive drugs. A-61603 is a selective α1A-adrenergic receptor agonist that is at least 35-fold more potent at α1A receptor sites than at α1B or α1D.{28349} Activation of the α1A-adrenergic receptor by A-61603 has been reported to increase the frequency of spontaneous Ca2+ transients in rat ventricular myocytes in vitro (EC50 = 6.9 nM) much more potently than activation by phenylephrine (Item No. 17205; EC50 = 2.3 µM).{28350}
Brand:CaymanSKU:-Available on backorder
The α1-adrenergic receptors are Gq protein-coupled receptors that play a key role in the modulation of sympathetic nervous system activity and are the site of action for therapeutic agents, such as antihypertensive drugs. A-61603 is a selective α1A-adrenergic receptor agonist that is at least 35-fold more potent at α1A receptor sites than at α1B or α1D.{28349} Activation of the α1A-adrenergic receptor by A-61603 has been reported to increase the frequency of spontaneous Ca2+ transients in rat ventricular myocytes in vitro (EC50 = 6.9 nM) much more potently than activation by phenylephrine (Item No. 17205; EC50 = 2.3 µM).{28350}
Brand:CaymanSKU:-Available on backorder
The α1-adrenergic receptors are Gq protein-coupled receptors that play a key role in the modulation of sympathetic nervous system activity and are the site of action for therapeutic agents, such as antihypertensive drugs. A-61603 is a selective α1A-adrenergic receptor agonist that is at least 35-fold more potent at α1A receptor sites than at α1B or α1D.{28349} Activation of the α1A-adrenergic receptor by A-61603 has been reported to increase the frequency of spontaneous Ca2+ transients in rat ventricular myocytes in vitro (EC50 = 6.9 nM) much more potently than activation by phenylephrine (Item No. 17205; EC50 = 2.3 µM).{28350}
Brand:CaymanSKU:-Available on backorder
A-66 is a potent, selective inhibitor of the PI3K isoform p110α (IC50 = 32 nM in a cell-free assay).{32579} It displays over 100-fold selectivity for p110α over other isoforms. A-66 is effective in vivo, suppressing the growth of SK-OV-3 tumor xenografts in mice.{32579} It also impairs all measures of in vivo insulin action in mice.{32580} A-66 partially suppresses B cell receptor-dependent Akt activation and proliferation.{31648}
Brand:CaymanSKU:-Available on backorder
A-66 is a potent, selective inhibitor of the PI3K isoform p110α (IC50 = 32 nM in a cell-free assay).{32579} It displays over 100-fold selectivity for p110α over other isoforms. A-66 is effective in vivo, suppressing the growth of SK-OV-3 tumor xenografts in mice.{32579} It also impairs all measures of in vivo insulin action in mice.{32580} A-66 partially suppresses B cell receptor-dependent Akt activation and proliferation.{31648}
Brand:CaymanSKU:-Available on backorder
A-66 is a potent, selective inhibitor of the PI3K isoform p110α (IC50 = 32 nM in a cell-free assay).{32579} It displays over 100-fold selectivity for p110α over other isoforms. A-66 is effective in vivo, suppressing the growth of SK-OV-3 tumor xenografts in mice.{32579} It also impairs all measures of in vivo insulin action in mice.{32580} A-66 partially suppresses B cell receptor-dependent Akt activation and proliferation.{31648}
Brand:CaymanSKU:-Available on backorder